Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Brain & Neurology

Protocol Report on the Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD) Study

This study will test whether t-PBM, a low-cost, accessible, and user-friendly intervention, has the potential to improve cognition and function in an aMCI and early AD population.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

This protocol report describes a planned randomized, double-blind, placebo-controlled trial testing 24 sessions of transcranial near-infrared photobiomodulation over 8 weeks in people with amnestic mild cognitive impairment or early Alzheimer's disease. The authors report that the study will assess efficacy, safety and cognition, and explore brain mechanisms. No results are reported in the abstract.

Who or what was studied
People with amnestic mild cognitive impairment or early Alzheimer's disease
Limits stated in the abstract
The abstract is a study protocol, so no outcomes are reported, and the authors describe prior evidence as preliminary.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Background

Alzheimer's disease's (AD) prevalence is projected to increase as the population ages and current treatments are minimally effective. Transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light penetrates into the cerebral cortex, stimulates the mitochondrial respiratory chain, and increases cerebral blood flow. Preliminary data suggests t-PBM may be efficacious in improving cognition in people with early AD and amnestic mild cognitive impairment (aMCI).

Methods

In this randomized, double-blind, placebo-controlled study with aMCI and early AD participants, we will test the efficacy, safety, and impact on cognition of 24 sessions of t-PBM delivered over 8 weeks. Brain mechanisms of t-PBM in this population will be explored by testing whether the baseline tau burden (measured with 18F-MK6240), or changes in mitochondrial function over 8 weeks (assessed with 31P-MRSI), moderates the changes observed in cognitive functions after t-PBM therapy. We will also use changes in the fMRI Blood-Oxygenation-Level-Dependent (BOLD) signal after a single treatment to demonstrate t-PBM-dependent increases in prefrontal cortex blood flow.

Conclusion

This study will test whether t-PBM, a low-cost, accessible, and user-friendly intervention, has the potential to improve cognition and function in an aMCI and early AD population.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a single study: what to check before relying on this kind of research.

Terms in this paper: Photobiomodulation, Transcranial photobiomodulation, Near-infrared, Functional magnetic resonance imaging, Mild cognitive impairment, Cerebral blood flow, Placebo-controlled. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies